Dopaminergic Dysfunction in Late-Life Depression

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 15, 2021

Primary Completion Date

April 30, 2026

Study Completion Date

July 30, 2026

Conditions
Late Life DepressionCognitive DeclineDepressive Disorder, Treatment-ResistantLevodopaGait Impairment
Interventions
DRUG

L-Dopa

"Generic 25/100mg carbidopa/levodopa (Sinemet)capsules will be administered in this study. Participants will begin randomized double blinded 3- week trial of Levodopa. Dose titration starting at 150 mg /daily to maximum of 450 mg daily three times a day for three weeks.~After one week of taper participants will enter step 2 phase of study where carbidopa/levodopa matched placebo will be administered for 3 weeks afterwards dose will be slowly tapered over next 7 days."

DRUG

Placebo

Step 1 (3 weeks) Carbidopa/levodopa-matched placebo capsules 3 times. Followed by 1 week of taper. Step2(3 weeks):150-450mg carbidopa/levodopa 3 times daily for three weeks .Followed by 1 week of taper.

Trial Locations (2)

15213

RECRUITING

University of Pittsburgh Medical Center, Pittsburgh

37212

RECRUITING

Vanderbilt Psychiatric Hospital, Nashville

All Listed Sponsors
collaborator

Emory University

OTHER

collaborator

University of Pittsburgh

OTHER

collaborator

University of Pittsburgh Medical Center

OTHER

collaborator

Rutgers University

OTHER

lead

Vanderbilt University Medical Center

OTHER

NCT04469959 - Dopaminergic Dysfunction in Late-Life Depression | Biotech Hunter | Biotech Hunter